Ovarian Cancer: Lifestyle, Diet and Nutrition

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–156. doi:10.1002/ijc.1440
   PubMed Web of Science ®Google Scholar
• Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer. 2019;125(Suppl 24):4623–4629. doi:10.1002/cncr.32544
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–1388. doi:10.1016/S0140-6736(13)62146-7
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66(6):1191–1308.
   PubMed Web of Science ®Google Scholar
• Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004;7(1A):187–200. doi:10.1079/phn2003588
   PubMed Web of Science ®Google Scholar
• Miller AB, Berrino F, Hill M, Pietinen P, Riboli E, Wahrendorf J. Diet in the aetiology of cancer: a review. Eur J Cancer. 1994;30A(2):207–220. discussion 220-8, doi:10.1016/0959-8049(94)90088-4
   PubMed Web of Science ®Google Scholar
• Grosso G, Bella F, Godos J, Sciacca S, Del Rio D, Ray S, Galvano F, Giovannucci EL. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutr Rev. 2017;75(6):405–419. doi:10.1093/nutrit/nux012
   PubMed Web of Science ®Google Scholar
• Albuquerque RC, Baltar VT, Marchioni DM. Breast cancer and dietary patterns: a systematic review. Nutr Rev. 2014;72(1):1–17. doi:10.1111/nure.12083
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Rosato V, Andreano A, Ferraroni M, Decarli A, Edefonti V, La Vecchia C. Dietary patterns and gastric cancer risk: a systematic review and meta-analysis. Ann Oncol. 2013;24(6):1450–1458. doi:10.1093/annonc/mdt108
   PubMed Web of Science ®Google Scholar
• Liu X, Wang X, Lin S, Yuan J, Yu IT. Dietary patterns and oesophageal squamous cell carcinoma: a systematic review and meta-analysis. Br J Cancer. 2014;110(11):2785–2795. doi:10.1038/bjc.2014.172
   PubMed Web of Science ®Google Scholar
• Magalhaes B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev. 2012;21(1):15–23. doi:10.1097/CEJ.0b013e3283472241
   PubMed Web of Science ®Google Scholar
• Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 1975;15(4):617–31. doi:10.1002/ijc.2910150411
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Cancer: Causes, occurence and control. Vol. 100. Lyon, France: IARC Scientific Publications; 1990.
   Google Scholar
• Ferlay J, Bray P, Pisani P, Parkin DM, et al. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0 International Agency for Research on Cancer (IARCPress): Lyon, France, 2001. Url: http://gco.iarc.fr/C15plus.
   Google Scholar
• Giacosa A, Barale R, Bavaresco L, Gatenby P, Gerbi V, Janssens J, Johnston B, Kas K, La Vecchia C, Mainguet P, et al. Cancer prevention in Europe: the Mediterranean diet as a protective choice. Eur J Cancer Prev. 2013;22(1):90–95. doi:10.1097/CEJ.0b013e328354d2d7
   PubMed Web of Science ®Google Scholar
• Moore SC, Lee I-M, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, Keadle SK, Arem H, Berrington de Gonzalez A, Hartge P, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med. 2016;176(6):816–825. doi:10.1001/jamainternmed.2016.1548
   PubMed Web of Science ®Google Scholar
• Abid Z, Cross AJ, Sinha R. Meat, dairy, and cancer. Am J Clin Nutr. 2014;100(Suppl 1):386S–393S. doi:10.3945/ajcn.113.071597
   PubMed Web of Science ®Google Scholar
• Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–593. doi:10.1038/bjc.2014.579
   PubMed Web of Science ®Google Scholar
• Shield KD, Soerjomataram I, Rehm J. Alcohol use and breast cancer: A critical review. Alcohol Clin Exp Res. 2016;40(6):1166–1181. doi:10.1111/acer.13071
   PubMed Web of Science ®Google Scholar
• Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578. doi:10.1016/S0140-6736(08)60269-X
   PubMed Web of Science ®Google Scholar
• Choi Y, Giovannucci E, Lee JE. Glycaemic index and glycaemic load in relation to risk of diabetes-related cancers: a meta-analysis. Br J Nutr. 2012;108(11):1934–1947. doi:10.1017/S0007114512003984
   PubMed Web of Science ®Google Scholar
• Report of the Joint WHO/FAO Consultation. Diet, nutrition and the prevention of chronic diseases. WHO Technical Report Series Edition 916; 2003. https://www.who.int/dietphysicalactivity/publications/trs916/en/
   Google Scholar
• Wei T, Ye P, Peng X, Wu LL, Yu GY. Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies. Oncotarget. 2016;7(30):48671–48691. doi:10.18632/oncotarget.8932
   PubMedGoogle Scholar
• Alderton G. Chronic inflammation as a cancer driver. Science. 2019;365(6452):135–137. doi:10.1126/science.365.6449.135-p
   Google Scholar
• Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–594. doi:10.1210/er.2011-1015
   PubMed Web of Science ®Google Scholar
• Hursting SD. Obesity, energy balance, and cancer: a mechanistic perspective. Cancer Treat Res. 2014;159:21–33. doi:10.1007/978-3-642-38007-5_2
   PubMedGoogle Scholar
• Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep. 2018;8(1):12394. doi:10.1038/s41598-018-30261-8
   PubMed Web of Science ®Google Scholar
• Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Goff DV, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34(3):362–366. doi:10.1093/ajcn/34.3.362
   PubMed Web of Science ®Google Scholar
• Salmerón J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA. 1997;277(6):472–477. doi:10.1001/jama.1997.03540300040031
   PubMed Web of Science ®Google Scholar
• Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. Br J Cancer. 2008;99(3):434–441. doi:10.1038/sj.bjc.6604496
   PubMed Web of Science ®Google Scholar
• Augustin LS, Franceschi S, Jenkins DJ, Kendall CW, La Vecchia C. Glycemic index in chronic disease: a review. Eur J Clin Nutr. 2002;56(11):1049–1071. doi:10.1038/sj.ejcn.1601454
   PubMed Web of Science ®Google Scholar
• Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005;14(1):98–107.
   PubMed Web of Science ®Google Scholar
• Turati F, Galeone C, Augustin LSA, La Vecchia C. Glycemic index, glycemic load and cancer risk: An updated meta-analysis. Nutrients. 2019;11(10):2342. doi:10.3390/nu11102342
   PubMed Web of Science ®Google Scholar
• World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007. https://www.wcrf.org/dietandcancer/contents.
   Google Scholar
• Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V, WHO International Agency For Research on Cancer Monograph Working Group. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8(12):1065–1066. doi:10.1016/S1470-2045(07)70373-X
   PubMed Web of Science ®Google Scholar
• Costa G, Haus E, Stevens R. Shift work and cancer - considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 2010;36(2):163–179. doi:10.5271/sjweh.2899
   PubMed Web of Science ®Google Scholar
• Mirick DK, Davis S. Melatonin as a biomarker of circadian dysregulation. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3306–3313. doi:10.1158/1055-9965.EPI-08-0605
   PubMed Web of Science ®Google Scholar
• Adriaens I, Jacquet P, Cortvrindt R, Janssen K, Smitz J. Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesis. Toxicology. 2006;228(2–3):333–343. doi:10.1016/j.tox.2006.09.018
   PubMed Web of Science ®Google Scholar
• Voordouw BC, Euser R, Verdonk RE, Alberda BT, de Jong FH, Drogendijk AC, Fauser BC, Cohen M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab. 1992;74(1):108–117. doi:10.1210/jcem.74.1.1727807
   PubMed Web of Science ®Google Scholar
• Treeck O, Haldar C, Ortmann O. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep. 2006;15(1):231–235. doi:10.3892/or.15.1.231
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov. 2011;5(2):109–123. doi:10.2174/187221411799015408
   PubMedGoogle Scholar
• Futagami M, Sato S, Sakamoto T, Yokoyama Y, Saito Y. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells. Gynecol Oncol. 2001;82(3):544–549. doi:10.1006/gyno.2001.6330
   PubMed Web of Science ®Google Scholar
• Shellard SA, Whelan RD, Hill BT. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. Br J Cancer. 1989;60(3):288–290. doi:10.1038/bjc.1989.272
   PubMed Web of Science ®Google Scholar
• Bartsch H, Buchberger A, Franz H, Bartsch C, Maidonis I, Mecke D, Bayer E. Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. Life Sci. 2000;67(24):2953–2960. doi:10.1016/S0024-3205(00)00882-1
   PubMed Web of Science ®Google Scholar
• Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res. 1999;26(3):129–136. doi:10.1111/j.1600-079x.1999.tb00574.x
   PubMed Web of Science ®Google Scholar
• Papazisis KT, Kouretas D, Geromichalos GD, Sivridis E, Tsekreli OK, Dimitriadis KA, Kortsaris AH. Effects of melatonin on proliferation of cancer cell lines. J Pineal Res. 1998;25(4):211–218. doi:10.1111/j.1600-079x.1998.tb00390.x
   PubMed Web of Science ®Google Scholar
• Chuffa LGA, Fioruci-Fontanelli BA, Mendes LO, Fávaro WJ, Pinheiro PFF, Martinez M, Martinez FE. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. PLoS One. 2013;8(12):e81676. doi:10.1371/journal.pone.0081676
   PubMed Web of Science ®Google Scholar
• Moore CB, Siopes TD. Spontaneous ovarian adenocarcinoma in the domestic turkey breeder hen (Meleagris gallopavo): effects of photoperiod and melatonin. Neuro Endocrinol Lett. 2004;25(1–2):94–101. PMID: 15159691.
   PubMed Web of Science ®Google Scholar
• Bhatti P, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Nightshift work and risk of ovarian cancer. Occup Environ Med. 2013;70(4):231–237. doi:10.1136/oemed-2012-101146
   PubMed Web of Science ®Google Scholar
• Pinkerton LE, Hein MJ, Anderson JL, Christianson A, Little MP, Sigurdson AJ, Schubauer-Berigan MK. Melanoma, thyroid cancer, and gynecologic cancers in a cohort of female flight attendants. Am J Ind Med. 2018;61(7):572–581. doi:10.1002/ajim.22854
   PubMed Web of Science ®Google Scholar
• Poole EM, Schernhammer E, Mills L, Hankinson SE, Tworoger SS. Urinary melatonin and risk of ovarian cancer. Cancer Causes Control. 2015;26(10):1501–1506. doi:10.1007/s10552-015-0640-2
   PubMed Web of Science ®Google Scholar
• Han B, Li X, Yu T. Cruciferous vegetables consumption and the risk of ovarian cancer: a meta-analysis of observational studies. Diagn Pathol. 2014;9:7. doi:10.1186/1746-1596-9-7
   PubMed Web of Science ®Google Scholar
• Hu J, Hu Y, Hu Y, Zheng S. Intake of cruciferous vegetables is associated with reduced risk of ovarian cancer: a meta-analysis. Asia Pac J Clin Nutr. 2015;24(1):101–109. doi:10.6133/apjcn.2015.24.1.22
   PubMed Web of Science ®Google Scholar
• Jiang PY, Jiang ZB, Shen KX, Yue Y. Fish intake and ovarian cancer risk: a meta-analysis of 15 case-control and cohort studies. PLoS One. 2014;9(4):e94601. doi:10.1371/journal.pone.0094601
   PubMed Web of Science ®Google Scholar
• Gao M, Ma W, Chen X-B, Chang Z-W, Zhang X-D, Zhang M-Z. Meta-analysis of green tea drinking and the prevalence of gynecological tumors in women. Asia Pac J Public Health. 2013;25(4_suppl):43S–48S.9513493313 doi:10.1177/101053
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9:e1001200. doi:10.1371/journal.pmed.1001200
   PubMed Web of Science ®Google Scholar
• Zhong S, Chen L, Lv M, Ma T, Zhang X, Zhao J. Nonoccupational physical activity and risk of ovarian cancer: a meta-analysis. Tumour Biol. 2014;35(11):11065–11073. doi:10.1007/s13277-014-2385-z
   PubMedGoogle Scholar
• Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Chang-Claude J, Köbel M, Ovarian Cancer Association Consortium, et al. Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer. 2013;13:28. doi:10.1186/1471-2407-13-28
   PubMed Web of Science ®Google Scholar
• Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, Negri E, Boffetta P, Bellocco R, Corrao G, et al. Alcohol drinking and epithelial ovarian cancer risk. A systematic review and meta-analysis. Gynecol Oncol. 2012;125(3):758–763. doi:10.1016/j.ygyno.2012.03.031
   PubMed Web of Science ®Google Scholar
• Yan-Hong H, Jing L, Hong L, Shan-Shan H, Yan L, Ju L. Association between alcohol consumption and the risk of ovarian cancer: a meta-analysis of prospective observational studies. BMC Public Health. 2015;15:223. doi:10.1186/s12889-015-1355-8
   PubMed Web of Science ®Google Scholar
• Faber MT, Kjaer SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, Webb PM, Jordan SJ, Rossing MA, Doherty JA, Ovarian Cancer Association Consortium, et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control. 2013;24(5):989–1004. doi:10.1007/s10552-013-0174-4
   PubMed Web of Science ®Google Scholar
• Beral V, Gaitskell K, Hermon C, Moser K, Collaborative Group on Epidemiological Studies of Ovarian Cancer, et al. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–956. doi:10.1016/S1470-2045(12)70322-4
   PubMed Web of Science ®Google Scholar
• Li D-P, Du C, Zhang Z-M, Li G-X, Yu Z-F, Wang X, Li P-F, Cheng C, Liu Y-P, Zhao Y-S, et al. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. Asian Pac J Cancer Prev. 2014;15(12):4829–4837. doi:10.7314/APJCP.2014.15.12.4829
   PubMedGoogle Scholar
• Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. J Ovarian Res. 2012;5(1):13. doi:10.1186/1757-2215-5-13
   PubMed Web of Science ®Google Scholar
• Beral V, Doll R, Hermon C, Peto R, Collaborative Group on Epidemiological Studies of Ovarian Cancer, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–314. doi:10.1016/S0140-6736(08)60167-1
   PubMed Web of Science ®Google Scholar
• Beral V, Gaitskell K, Hermon C, Moser K, Collaborative Group on Epidemiological Studies of Ovarian Cancer, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385:1835–1842. doi:10.1016/S0140-6736(14)61687-1
   PubMed Web of Science ®Google Scholar
• Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, Kjaer SK. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand. 2013;92(3):245–255. doi:10.1111/aogs.12069
   PubMed Web of Science ®Google Scholar
• Ni X, Ma J, Zhao Y, Wang Y, Wang S. Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. Br J Clin Pharmacol. 2013;75(1):26–35. doi:10.1111/j.1365-2125.2012.04290.x
   PubMed Web of Science ®Google Scholar
• Trabert B, Ness RB, Lo-Ciganic W-H, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Australian Ovarian Cancer Study Group, the Australian Cancer Study (Ovarian Cancer), et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;106(2):djt431. doi:10.1093/jnci/djt431
   PubMedGoogle Scholar
• Cannioto RA, Moysich KB. Epithelial ovarian cancer and recreational physical activity: A review of the epidemiological literature and implications for exercise prescription. Gynecol Oncol. 2015;137(3):559–573. doi:10.1016/j.ygyno.2015.03.016
   PubMed Web of Science ®Google Scholar
• Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SAA, Pettinger M, Lane DS, Lessin L, Yasmeen S, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative dietary modification randomized controlled trial. J Natl Cancer Inst. 2007;99(20):1534–1543. doi:10.1093/jnci/djm159
   PubMedGoogle Scholar
• Bertone ER, Rosner BA, Hunter DJ, Stampfer MJ, Speizer FE, Colditz GA, Willett WC, Hankinson SE. Dietary fat intake and ovarian cancer in a cohort of US women. Am J Epidemiol. 2002;156(1):22–31. doi:10.1093/aje/kwf008
   PubMed Web of Science ®Google Scholar
• Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K, Thomson CA. Dietary intake and ovarian cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23(2):255–273. doi:10.1158/1055-9965.EPI-13-0515
   PubMed Web of Science ®Google Scholar
• Chandran U, Bandera EV, Williams-King MG, Paddock LE, Rodriguez-Rodriguez L, Lu S-E, Faulkner S, Pulick K, Olson SH. Healthy eating index and ovarian cancer risk. Cancer Causes Control. 2011;22(4):563–571. doi:10.1007/s10552-011-9728-5
   PubMed Web of Science ®Google Scholar
• Xie J, Poole EM, Terry KL, Fung TT, Rosner BA, Willett WC, Tworoger SS. A prospective cohort study of dietary indices and incidence of epithelial ovarian cancer. J Ovarian Res. 2014;7:112. doi:10.1186/s13048-014-0112-4
   PubMed Web of Science ®Google Scholar
• Liu J, Tang W, Sang L, Dai X, Wei D, Luo Y, Zhang J. Milk, yogurt, and lactose intake and ovarian cancer risk: a meta-analysis. Nutr Cancer. 2015;67(1):68–72. doi:10.1080/01635581.2014.956247
   PubMed Web of Science ®Google Scholar
• Monteiro Â, Colomban S, Azinheira HG, Guerra-Guimarães L, Do Céu Silva M, Navarini L, Resmini M. Dietary antioxidants in coffee leaves: Impact of botanical origin and maturity on chlorogenic acids and xanthones. Anitoxidants. 2019;9(1):6. doi:10.3390/antiox9010006
   Web of Science ®Google Scholar
• Yan Z, Zhong Y, Duan Y, Chen Q, Li F. Antioxidant mechanism of tea polyphenols and its impact on health benefits. Anim Nutr. 2020;6(2):115–123. doi:10.1016/j.anainu.2020.01.001
   PubMed Web of Science ®Google Scholar
• Braem MGM, Onland-Moret NC, Schouten LJ, Tjønneland A, Hansen L, Dahm CC, Overvad K, Lukanova A, Dossus L, Floegel A, et al. Coffee and tea consumption and the risk of ovarian cancer: a prospective cohort study and updated meta-analysis. Am J Clin Nutr. 2012;95(5):1172–1181. doi:10.3945/ajcn.111.026393
   PubMed Web of Science ®Google Scholar
• Gosvig CF, Kjaer SK, Blaakaer J, Høgdall E, Høgdall C, Jensen A. Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. Acta Oncol. 2015;54(8):1144–1151. doi:10.3109/0284186X.2014.1001035
   PubMed Web of Science ®Google Scholar
• Oppeneer SJ, Robien K. Tea consumption and epithelial ovarian cancer risk: a systematic review of observational studies. Nutr Cancer. 2011;63(6):817–826. doi:10.1080/01635581.2011.594210
   PubMed Web of Science ®Google Scholar
• Cassidy A, Huang T, Rice MS, Rimm EB, Tworoger SS. Intake of dietary flavonoids and risk of epithelial ovarian cancer. Am J Clin Nutr. 2014;100(5):1344–1351. doi:10.3945/ajcn.114.088708
   PubMed Web of Science ®Google Scholar
• King MG, Olson SH, Paddock L, Chandran U, Demissie K, Lu S-E, Parekh N, Rodriguez-Rodriguez L, Bandera EV. Sugary food and beverage consumption and epithelial ovarian cancer risk: a population-based case-control study. BMC Cancer. 2013;13:94. doi:10.1186/1471-2407-13-94
   PubMed Web of Science ®Google Scholar
• Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Glycaemic index, glycaemic load and ovarian cancer risk: a prospective cohort study. Public Health Nutr. 2007;10(10):1076–1081. doi:10.1017/S1368980007696360
   PubMed Web of Science ®Google Scholar
• Tasevska N, Jiao L, Cross AJ, Kipnis V, Subar AF, Hollenbeck A, Schatzkin A, Potischman N. Sugars in diet and risk of cancer in the NIH-AARP Diet and Health Study. Int J Cancer. 2012;130(1):159–169. doi:10.1002/ijc.25990
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer. 2008;112(5):1169–1177. doi:10.1002/cncr.23275
   PubMed Web of Science ®Google Scholar
• Feng LP, Chen HL, Shen MY. Breastfeeding and the risk of ovarian cancer: a meta-analysis. J Midwifery Womens Health. 2014;59(4):428–437. doi:10.1111/jmwh.12085
   PubMed Web of Science ®Google Scholar
• Walker JL, Powell CB, Chen L-M, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108–2120. doi:10.1002/cncr.29321
   PubMed Web of Science ®Google Scholar
• Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150. doi:10.1186/s12905-014-0150-5
   PubMed Web of Science ®Google Scholar
• Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007;109(3):597–607. doi:10.1097/01.AOG.0000255664.48970.e6
   PubMed Web of Science ®Google Scholar
• Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, Sitas F. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med. 2012;9(3):e1001182. doi:10.1371/journal.pmed.1001182
   PubMed Web of Science ®Google Scholar
• Wilailak S, Vipupinyo C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y, Therasakvichya S, Hamontri S, Linasmita V, Bunyapipat S, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG. 2012;119(6):672–677. doi:10.1111/j.1471-0528.2012.03298.x
   PubMed Web of Science ®Google Scholar
• Anon. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of neoplasia and steroid contraceptives. Int J Cancer. 1991;49:191–195.
   PubMed Web of Science ®Google Scholar
• Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA. 1983;249(21):2909–2912.
   PubMed Web of Science ®Google Scholar
• Dorjgochoo T, Shu X-O, Li H-L, Qian H-Z, Yang G, Cai H, Gao Y-T, Zheng W. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer. 2009;124(10):2442–2449. doi:10.1002/ijc.24232
   PubMed Web of Science ®Google Scholar
• Huang Z, Gao Y, Wen W, Li H, Zheng W, Shu X-O, Beeghly-Fadiel A. Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study. Int J Cancer. 2015;137(3):607–614. doi:10.1002/ijc.29412
   PubMed Web of Science ®Google Scholar
• Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 1989;49(13):3670–3674.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003;290(13):1739–1748. doi:10.1001/jama.290.13.1739
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Writing Group for the Women's Health Initiative Investigators, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi:10.1001/jama.288.3.321
   PubMed Web of Science ®Google Scholar
• Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer. 2007;96(1):151–156. doi:10.1038/sj.bjc.6603527
   PubMed Web of Science ®Google Scholar
• Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol. 2013;130(3):615–619. doi:10.1016/j.ygyno.2013.05.025
   PubMed Web of Science ®Google Scholar
• Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis ADM, Richardson A. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol. 2013;129(2):417–424. doi:10.1016/j.ygyno.2013.02.003
   PubMed Web of Science ®Google Scholar
• Cook NR, Lee I-M, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55. doi:10.1001/jama.294.1.47
   PubMed Web of Science ®Google Scholar
• Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, Sherman ME, Hollenbeck A, Wentzensen N. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012;23(11):1839–1852. doi:10.1007/s10552-012-0063-2
   PubMed Web of Science ®Google Scholar
• Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol. 2009;169(11):1378–1387. doi:10.1093/aje/kwp062
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu J, Zhang H, Liu Y, Sun H. Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity. Am J Transl Res. 2018;10(10):3086–3098.
   PubMed Web of Science ®Google Scholar
• Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011;15(1):166–178. doi:10.1111/j.1582-4934.2009.00954.x
   PubMed Web of Science ®Google Scholar
• Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011;13(5):483–491. doi:10.1593/neo.11148
   PubMed Web of Science ®Google Scholar
• Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang C-Y, Loth R, Lastra R, McGregor SM, Locasale JW, et al. SPHK1 is a novel target of metformin in ovarian cancer. Mol Cancer Res. 2019;17(4):870–881. doi:10.1158/1541-7786.MCR-18-0409
   PubMed Web of Science ®Google Scholar
• Ma L, Wei J, Wan J, Wang W, Wang L, Yuan Y, Yang Z, Liu X, Ming L. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res. 2019;38(1):77. doi:10.1186/s13046-019-1090-6
   PubMed Web of Science ®Google Scholar
• Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, Ning Z, Wang J, Xu X, Jiang Y, et al. Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis. Cancer Lett. 2019;450:22–31. doi:10.1016/j.canlet.2019.02.014
   PubMed Web of Science ®Google Scholar
• Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011;123(2):200–204. doi:10.1016/j.ygyno.2011.06.038
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 2015;138(1):147–153. doi:10.1016/j.ygyno.2015.03.059
   PubMed Web of Science ®Google Scholar
• Shah MM, Erickson BK, Matin T, McGwin G, Martin JY, Daily LB, Pasko D, Haygood CW, Fauci JM, Leath CA, et al. Diabetes mellitus and ovarian cancer: more complex than just increasing risk. Gynecol Oncol. 2014;135(2):273–277. doi:10.1016/j.ygyno.2014.09.004
   PubMed Web of Science ®Google Scholar
• Soffer D, Shi J, Chung J, Schottinger JE, Wallner LP, Chlebowski RT, Lentz SE, Haque R. Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care. 2015;3(1):e000049. doi:10.1136/bmjdrc-2014-000049
   PubMed Web of Science ®Google Scholar
• Nagle CM, Purdie DM, Webb PM, Green A, Harvey PW, Bain CJ. Dietary influences on survival after ovarian cancer. Int J Cancer. 2003;106(2):264–269. doi:10.1002/ijc.11204
   PubMed Web of Science ®Google Scholar
• Dolecek TA, McCarthy BJ, Joslin CE, Peterson CE, Kim S, Freels SA, Davis FG. Prediagnosis food patterns are associated with length of survival from epithelial ovarian cancer. J Am Diet Assoc. 2010;110(3):369–382. doi:10.1016/j.jada.2009.11.014
   PubMedGoogle Scholar
• Thomson CA, Ec T, Wertheim BC, Neuhouser ML, Li W, et al. Diet quality and survival after ovarian cancer: results from the Women's Health Initiative. J Natl Cancer Inst. 2014;106:1–8. doi:10.1093/jnci/dju314
   Google Scholar
• Langenberg C, Sharp SJ, Schulze MB, Rolandsson O, InterAct Consortium, et al. Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. PLoS Med. 2012;9:e1001230. doi:10.1371/journal.pmed.1001230
   PubMed Web of Science ®Google Scholar
• Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174. doi:10.1155/2012/789174
   PubMed Web of Science ®Google Scholar
• Bakhru A, Buckanovich RJ, Griggs JJ. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol. 2011;121(1):106–111. doi:10.1016/j.ygyno.2010.12.329
   PubMed Web of Science ®Google Scholar
• Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012;119(1):61–67. doi:10.1097/AOG.0b013e3182393ab3
   PubMed Web of Science ®Google Scholar
• Moorman PG, Jones LW, Akushevich L, Schildkraut JM. Recreational physical activity and ovarian cancer risk and survival. Ann Epidemiol. 2011;21(3):178–187. doi:10.1016/j.annepidem.2010.10.014
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, Lavasani S, Walsh BW, Anderson G, Vitolins M, et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative. Gynecol Oncol. 2014;133(1):4–10. doi:10.1016/j.ygyno.2014.01.033
   PubMed Web of Science ®Google Scholar
• Willet WC, Sampson L. 24-Hour recall and diet record methods. In: Willet WC, editor. Nutritional epidemiology. 3rd ed. New York (NY): Oxford University Press; 2012. https://read.amazon.co.uk
   Google Scholar
• Giovannucci E, Stampfer MJ, Colditz GA, Manson JE, Rosner BA, Longnecker M, Speizer FE, Willett WC. A comparison of prospective and retrospective assessments of diet in the study of breast cancer. Am J Epidemiol. 1993;137(5):502–511. doi:10.1093/oxfordjournals.aje.a116703
   PubMed Web of Science ®Google Scholar
• Euser AM, Zoccali C, Jager KJ, Dekker FW. Cohort studies: prospective versus retrospective. Nephron Clin Pract. 2009;113(3):c214–c217. doi:10.1159/000235241
   PubMedGoogle Scholar
• Hu F. Issues in analysis and presentation of dietary data. In: Willet WC, editor. Nutritional epidemiology. 3rd ed. New York (NY): Oxford University Press; 2012. https://read.amazon.co.uk
   Google Scholar
• Carroll RJ, Ruppert D, Stefanski LA, Crainiceanu CM. Chapter 2, Important concepts. In: Measurement error in nonlinear models: A modern perspective. 2nd ed. Boca Raton: Chapman and Hall/CRC Press; 2006. p. 25–29. doi:10.1201/9781420010138
   Google Scholar
• Gustafson P. Section 6.2, Mismeasurement bias and model misspecification bias. In: Measurement error and misclassification in statistics and epidemiology: impacts and Bayesian adjustments. Boca Raton: Chapman and Hall/CRC Press; 2003. https://b-ok.cc/book/668191/2dc86f.
   Google Scholar
• Fuller WA. Chapter 1, section 6.3, Measurement error and prediction. In: Measurement error models. New York: Wiley; 2009. p. 74–78. https://www.amazon.com/Measurement-Error-Models-Wayne-Fuller/dp/0470095717
   Google Scholar
• Buonaccorsi JP. Chapter 6, Measurement error in regression: A general overview. In: Measurement error: models, methods, and applications. Boca Raton: Chapman and Hall/CRC Press; 2010. p. 143–222. https://b-ok.cc/book/1270745/dc9065
   Google Scholar
• Armstrong BK, Saracci R. Reducing measurement error and its effect. In: White E, Armstrong BK, Saracci R, editors. Principles of exposure measurement in epidemiology: collecting, evaluating and improving measures of disease risk factors. Oxford, UK: Oxford University Press; 2008. pp. 141–174. doi:10.1093/acprof:oso/9780198509851.003.0005
   Google Scholar
• Shaw PA, Deffner V, Keogh RH, Tooze JA, Dodd KW, Küchenhoff H, Kipnis V, Freedman LS, Measurement Error and Misclassification Topic Group (TG4) of the STRATOS Initiative. Epidemiologic analyses with error-prone exposures: review of current practice and recommendations. Ann Epidemiol. 2018;28(11):821–828. doi:10.1016/j.annepidem.2018.09.001
   PubMed Web of Science ®Google Scholar